EP Patent

EP1790339A1 — Composition for prevention of occurrence of cardiovascular event

Assigned to Mochida Pharmaceutical Co Ltd · Expires 2007-05-30 · 19y expired

What this patent protects

Provided is composition, containing ethyl icosapentate as its effective component, which is useful in preventing onset and/or recurrence of cardiovascular events; especially expected is preventive effect of onset and/or recurrence of those which occur or recur irrespective of the…

USPTO Abstract

Provided is composition, containing ethyl icosapentate as its effective component, which is useful in preventing onset and/or recurrence of cardiovascular events; especially expected is preventive effect of onset and/or recurrence of those which occur or recur irrespective of the treatment with HMG-CoA RI in hyperlipidemia patients and those which occur after the unstable period after cardiovascular angioplasty is over.

Drugs covered by this patent

Patent Metadata

Patent number
EP1790339A1
Jurisdiction
EP
Classification
—
Expires
2007-05-30
Drug substance claim
No
Drug product claim
No
Assignee
Mochida Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.